The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis

References

• Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011 Feb 10;29(5):573–14. doi:10.1200/JCO.2010.29.8711.
   PubMed Web of Science ®Google Scholar
• Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 May 29;123(22):e123–33. doi:10.1182/blood-2014-02-554634.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011 Apr 1;29(10):1356–1363. doi:10.1200/JCO.2010.32.9490.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012 Apr 5;119(14):3219–3225. doi:10.1182/blood-2011-11-394775.
   PubMed Web of Science ®Google Scholar
• Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG. Mo key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression. and symptoms. Curr Hematol Malig Rep. 2019 Jun;14(3):145–153. doi:10.1007/s11899-019-00508-w.
   PubMed Web of Science ®Google Scholar
• Sollazzo D, Forte D, Polverelli N, Romano M, Perricone M, Rossi L, Ottaviani E, Luatti S, Martinelli G, Vianelli N et al. Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. Oncotarget. 2016 Jul 12;7(28):43974–43988. doi:10.18632/oncotarget.9949.
   PubMedGoogle Scholar
• Mondet J, Hussein K, Mossuz P. Circulating cytokine levels as markers of inflammation in philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest. Mediators Inflamm. 2015;2015:670580. doi:10.1155/2015/670580.
   PubMed Web of Science ®Google Scholar
• Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. 2019 Feb 4;33(8):1978–1995. doi:10.1038/s41375-019-0379-y.
   PubMed Web of Science ®Google Scholar
• Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, O’Hare T et al. Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. Leukemia. 2018 Nov;32(11):2399–2411. doi:10.1038/s41375-018-0131-z.
   PubMed Web of Science ®Google Scholar
• Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol. 2017 Jan;92(1):37–41. doi:10.1002/ajh.24572.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory J-L, Barosi G et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood. 2009 Mar 26;113(13):2895–2901. doi:10.1182/blood-2008-07-170449.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 Mar 4;115(9):1703–1708. doi:10.1182/blood-2009-09-245837.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf ÅR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015 Jul 10;33(20):2288–2295. doi:10.1200/JCO.2014.57.6652.
   PubMed Web of Science ®Google Scholar
• Froom P, Aghai E, Kinarty A, Lahat N. Decreased natural killer (NK) activity in patients with myeloproliferative disorders. Cancer. 1989 Sep 1;64(5):1038–1040. doi:10.1002/1097-0142(19890901)64:5<1038::AID-CNCR2820640513>3.0.CO;2-W.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Hernández-Boluda JC, Villamor N, Serra A, Montserrat E. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol. 2000 Aug;65(2):104–108. doi:10.1034/j.1600-0609.2000.90262.x.
   PubMed Web of Science ®Google Scholar
• Briard D, Brouty-Boyé D, Giron-Michel J, Azzarone B, Jasmin C, Le Bousse-Kerdilès C. Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol. 2003 Mar;106(3):201–212. doi:10.1016/S1521-6616(02)00046-3.
   PubMed Web of Science ®Google Scholar
• Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014 Dec;9(4):331–339. doi:10.1007/s11899-014-0227-0.
   PubMed Web of Science ®Google Scholar
• Wang JC, Sindhu H, Chen C, Kundra A, Kafeel MI, Wong C, Lichter S. Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα. PLoS One. 2015 Mar 20;10(3):e0116723. doi:10.1371/journal.pone.0116723.
   PubMed Web of Science ®Google Scholar
• Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C, Sindhu H. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res. 2016 Apr;43:39–43. Epub 2016 Feb 16. doi:10.1016/j.leukres.2016.02.004.
   PubMed Web of Science ®Google Scholar
• Massa M, Campanelli R, Fois G, Villani L, Bonetti E, Catarsi P, Poletto V, Viarengo G, De Amici M, Rosti V et al. Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood. 2016 Sep 22;128(12):1660–1662. doi:10.1182/blood-2016-03-704577.
   PubMed Web of Science ®Google Scholar
• Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, Forte D, Luatti S, Cavo M, Vianelli N, et al. Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. Oncoimmunology. 2017 Jul 5;6(10):e1345402. eCollection 2017. doi:10.1080/2162402X.2017.1345402.
   PubMed Web of Science ®Google Scholar
• Parampalli YS, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015 Jun;169(6):824–833. doi:10.1111/bjh.13373.
   PubMed Web of Science ®Google Scholar
• Schönberg K, Rudolph J, Vonnahme M, Parampalli YS, Cornez I, Hejazi M, Manser AR, Uhrberg M, Verbeek W, Koschmieder S et al. JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Res. 2015 Jun 1;75(11):2187–2199. doi:10.1158/0008-5472.CAN-14-3198.
   PubMed Web of Science ®Google Scholar
• Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NSB, Harrison CN, McLornan DP, Mufti GJ. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015 Oct;171(1):60–73. doi:10.1111/bjh.13519.
   PubMed Web of Science ®Google Scholar
• Rudolph J, Heine A, Quast T, Kolanus W, Trebicka J, Brossart P, Wolf D. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia. 2016 Oct;30(10):2119–2123. doi:10.1038/leu.2016.155.
   PubMed Web of Science ®Google Scholar
• Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014 Feb;28(2):449–451. doi:10.1038/leu.2013.296.
   PubMed Web of Science ®Google Scholar
• Schönberg K, Rudolph J, Yajnanarayana SP, Wolf D. Get a grip on immune cells by inhibiting JAKs. Oncoimmunology. 2015 Aug 12;5(2):e1071009. eCollection 2016 Feb. doi:10.1080/2162402X.2015.1071009.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncology. 2015;1:97–105. doi:10.1001/jamaoncol.2015.89.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018 Jan 17;7:82. eCollection 2018. doi:10.12688/f1000research.13167.1.
   PubMedGoogle Scholar
• Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical monocytes in health and disease. Annu Rev Immunol. 2019 Apr 26;37:439–456. doi:10.1146/annurev-immunol-042617-053119.
   PubMed Web of Science ®Google Scholar
• Sampath P, Moideen K, Ranganathan UD, Bethunaickan R. Monocyte subsets: phenotypes and function in tuberculosis infection. Front Immunol. 2018;9:1726. doi:10.3389/fimmu.2018.01726.
   PubMed Web of Science ®Google Scholar
• Wacleche VS, Tremblay CL, Routy JP, Ancuta P. The biology of monocytes and dendritic cells: contribution to HIV pathogenesis. Viruses. 2018 Feb;10(2):65. doi:10.3390/v10020065.
   PubMed Web of Science ®Google Scholar
• Fitzgerald W, Freeman ML, Lederman MM, Vasilieva E, Romero R, Margolis L. A system of cytokines encapsulated in extracellular vesicles. Sci Rep. 2018 Jun 12;8(1):8973. doi:10.1038/s41598-018-27190-x.
   PubMed Web of Science ®Google Scholar
• Butler JT, Abdelhamed S, Kurre P. Extracellular vesicles in the hematopoietic microenvironment. Haematologica. 2018;103:382–394. doi:10.3324/haematol.2017.183335.
   PubMed Web of Science ®Google Scholar
• Van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018 Apr;19(4):213–228. doi:10.1038/nrm.2017.125.
   PubMed Web of Science ®Google Scholar
• Robbins PD, Dorronsoro A, Booker CN. Regulation of chronic inflammatory and immune processes by extracellular vesicles. J Clin Invest. 2016 Apr 1;126(4):1173–1180. doi:10.1172/JCI81131.
   PubMed Web of Science ®Google Scholar
• Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S, D'Auria F, Traficante A, Maietti M, Izzoet T, et al. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biology. 2015;36:9739–9752. doi:10.1007/s13277-015-3741-3.
   PubMed Web of Science ®Google Scholar
• Zhang W, Qi J, Zhao S, Shen W, Dai L, Han W, Huang M, Wang Z, Ruan C, Wu D, et al. Clinical significance of circulating microparticles in Ph- Myeloproliferative Neoplasms. Oncol Lett. 2017;14(2):2531–2536. doi:10.3892/ol.2017.6459.
   PubMed Web of Science ®Google Scholar
• Barone M, Ricci F, Sollazzo D, Ottaviani E, Romano M, Auteri G, Bartoletti D, Reggiani MLB, Vianelli N, Tazzari PL et al. Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. Br J Haematol. 2019 Jun;185(5):987–991. doi:10.1111/bjh.15682.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007 Nov;31(11):1503–1509. doi:10.1016/j.leukres.2006.12.025.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol. 2000 Aug 15;165(4):2271–2277. doi:10.4049/jimmunol.165.4.2271.
   PubMed Web of Science ®Google Scholar
• Campanelli R, Rosti V, Fois G, Bonetti E, Barosi G, Massa M. CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Exp Hematol. 2014 Apr;42(4):244–246. doi:10.1016/j.exphem.2013.12.002.
   PubMed Web of Science ®Google Scholar
• De la Guardia RD, Correa JG, López-Millán B, Juan M, Bueno C, Cervantes F, Menéndez P. Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. Br J Haematol. 2018 Apr;181(1):133–137. doi:10.1111/bjh.14507.
   PubMed Web of Science ®Google Scholar
• Schuerwegh AJ, Stevens WJ, Bridts CH, De Clerck LS. Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes. Cytometry. 2001 Jun 15;46(3):172–176. doi:10.1002/cyto.1102.
   PubMedGoogle Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov 1;174(5):1209–1220. doi:10.1084/jem.174.5.1209.
   PubMed Web of Science ®Google Scholar
• Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011 Oct 10;11(11):762–774. doi:10.1038/nri3070.
   PubMed Web of Science ®Google Scholar
• Carey AJ, Tan CK, Ulett GC. Infection-induced IL-10 and JAK-STAT: a review of the molecular circuitry controlling immune hyperactivity in response to pathogenic microbes. JAKSTAT. 2012 Jul 1;1(3):159–167. doi:10.4161/jkst.19918.
   PubMedGoogle Scholar
• Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics. 2013 Nov;12(6):489–498. Epub 2013 Aug 12. doi:10.1093/bfgp/elt028.
   PubMed Web of Science ®Google Scholar
• Lai HY, Brooks SA, Craver BM, Morse SJ, Nguyen TK, Haghighi N, Garbati MR, Fleischman AG. Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm. Blood Adv. 2019 Jan 22;3(2):122–131. doi:10.1182/bloodadvances.2018026450.
   PubMed Web of Science ®Google Scholar
• Gane JM, Stockley RA, Sapey E. TNF-α autocrine feedback loops in human monocytes: the pro- and anti-inflammatory roles of the TNF-α receptors support the concept of selective TNFR1 blockade in vivo. J Immunol Res. 2016 Sep 22;2016:1079851. doi:10.1155/2016/1079851.
   PubMed Web of Science ®Google Scholar
• houval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, Muise AM, Snapper SB. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014;122:177–210. doi:10.1016/B978-0-12-800267-4.00005-5.
   PubMed Web of Science ®Google Scholar
• Zhengfan J, Philippe G, Xin D, Louis S, Sovath S, Mudd S, Huber M, Kalis C, Keck S, Galanos C, et al. CD14 is required for MyD88-independent LPS signalling. Nat Immunol. 2005;6:565–570. doi:10.1038/ni1207.
   PubMed Web of Science ®Google Scholar
• Paracha RZ, Ahmad J, Ali A, Hussain R, Niazi U, Tareen SHK, Aslam B. Formal modelling of toll like receptor 4 and JAK/STAT signalling pathways: insight into the roles of SOCS-1, Interferon-β and proinflammatory cytokines in sepsis. PLoS One. 2014;9(9):e108466. doi:10.1371/journal.pone.0108466.
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013 Aug 15;122(7):1192–1202. Epub 2013 Jun 14. doi:10.1182/blood-2013-03-484642.
   PubMed Web of Science ®Google Scholar
• Stalder R, Zhang B, Wrobel LJ, Boehncke WH, Brembilla NC. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development. Exp Dermatol. 2020 Jan;29(1):71–78. Epub 2019 Nov 26. doi:10.1111/exd.14059.
   PubMed Web of Science ®Google Scholar